C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease

Title: C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease

Volume: 2 Issue: 2

Author(s): Charles DeBattista and Joseph Belanoff

Affiliation:

Keywords: glucocorticoid II receptor, hypothalamic pituitary adrenal (hpa), psychotic major depression (pmd), hippocampus, progesterone, transcription, dna, cushing, ’, s disease, hypercortisolemia, bipolar affective disorder

Abstract: Alzheimers disease is frequently associated with abnormalities in the hypothalamic pituitary adrenal axis. Elevated cortisol levels in Alzheimers disease may in turn be associated with a more rapid progression of the illness. In addition, elevated cortisol levels may directly contribute to cognitive deficits in Alzheimers disease. Mifepristone is a potent antagonist of the glucocorticoid receptor and blocks the central actions of cortisol. The purpose of this study is to determine the effects of glucocorticoid receptor blockade with mifepristone on cognition in Alzheimers disease.

Cite this article as:

DeBattista Charles and Belanoff Joseph, C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585954